Natural Solution Provides Positive Mitigation Against Type 2 Diabetes
Plandai Biotechnology Inc. (OTC Markets: PLPL) (the “Company” or “Plandai”), a producer of nutraceutical and highly phyto-available extracts, is pleased to discuss green tea and its positive natural attributes in helping to prevent and fight Type 2 diabetes.
Generally, diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin it produces. Insulin is a hormone that regulates blood sugar. Hyperglycemia, or raised blood sugar, is a common effect of uncontrolled diabetes, and over time leads to serious damage to many of the body’s systems, especially the nerves and blood vessels.
Type 2 diabetes is a long-term metabolic disorder that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. Common symptoms include increased thirst, frequent urination, and unexplained weight loss. Symptoms may also include increased hunger, feeling tired, and sores that do not heal. Long-term complications from high blood sugar include heart disease, strokes, diabetic retinopathy, which can result in blindness, kidney failure, and poor blood flow in the limbs, which may lead to amputations.
While low vitamin D levels are associated with an increased risk of diabetes, Type 2 diabetes is partly preventable by maintaining a normal weight, exercising regularly, and eating properly through dietary changes. When blood sugar levels cannot be adequately lowered by life style changes, the medication Metformin is typically recommended to decrease liver glucose production. However, Metformin can cause considerable side effects.
In looking for a natural solution, epidemiological studies indicate that populations with a high intake of green tea catechins benefit in terms of body weight, body fat, the balance of insulin and glucagon, maintaining blood glucose, and cardiovascular health. This is particularly true considering the strong research data from in vitro and animal studies where actions from green tea catechins have shown decreased carbohydrate absorption, decreased hepatic glucose production (the inability of insulin to suppress hepatic glucose production is a key defect found in Type 2 diabetes) and increased insulin sensitivity (the relationship between how much insulin needs to be produced in order to deposit a certain amount of glucose).
Background information on diabetes:
Type 2 diabetes is increasingly prevalent but also largely preventable. According to the Centers for Disease Control and Prevention (CDC), type 2 diabetes accounts for about 90 to 95 percent of all diagnosed cases of diabetes in adults. Type 2 Diabetes prevalence has been rising more rapidly in middle- and low-income countries, and is a major cause of blindness, kidney failure, heart attacks, stroke and lower limb amputation. The World Health Organization (WHO) predicts that diabetes generally will be the seventh leading cause of death in 2030. Healthy diet, regular physical activity, maintaining a normal body weight and avoiding tobacco use are ways to prevent or delay the onset of Type 2 diabetes.
More than 29 million people in the United States have Type 2 diabetes, up from the previous estimate of 26 million in 2010, according to a report released today by the Centers for Disease Control and Prevention. One in four people with Type 2 diabetes doesn’t know he or she has it. Another 86 million adults – more than one in three U.S. adults – have prediabetes, where their blood sugar levels are higher than normal but not high enough to be classified as Type 2 diabetes. Without weight loss and moderate physical activity, 15 percent to 30 percent of people with prediabetes will develop Type 2 diabetes within five years.
About Plandai Biotechnology, Inc.
Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements and diabetes. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company’s future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company’s control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company’s current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company’s filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact InformationHayden IR(917) email@example.comMarlin MolinaroMarmel Communications, LLC(828) firstname.lastname@example.org
<img src=”http://www.globenewswire.com/newsroom/ti?ndecode=MTUwIzcyMjc1NTc=” alt=”” width=”1″ height=”1″/>